Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Clinical trial NCT01981837 · COMPLETED
Trial details
- NCT number
- NCT01981837
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.